Liver disease emerges as a burgeoning global health concern, presenting a myriad of formidable challenges. From viral hepatitis to alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), liver cirrhosis, and hepatocellular carcinoma (HCC), these conditions collectively afflict millions, exacting a toll of morbidity, mortality, and economic burden. Within this landscape, NAFLD/nonalcoholic steatohepatitis (NASH), recently renamed MASH (metabolic dysfunction-associated steatohepatitis), assumes prominence as a pivotal contributor. NAFLD, a comprehensive term encapsulating a spectrum of liver afflictions, encompasses everything from benign steatosis to progres...
